Sanofi bought into the nirsevimab programme in 2017, paying $645 million for marketing rights to the antibody, with AZ retaining the responsibility for developing and manufacturing it. Sobi also ...

Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

vaccine Beyfortus (nirsevimab), developed as part of a partnership with AstraZeneca. Whilst revealing its Q4 2024 results, Sanofi said it is planning to execute a $5.12bn share buyback programme ...

Sanofi declined to comment to Pharmaceutical ... preventative antibody Beyfortus (nirsevimab), developed in partnership with AstraZeneca. Positive financial guidance comes despite uncertainty ...

Nirsevimab was developed in partnership with ... The final medicine on the list is BTKi (‘168), described by Sanofi as an oral medicine for multiple sclerosis with potential to be the first ...

The Sanofi Global Health Unit plays an important ... we have a competitive profile with nirsevimab. We have an extensive amount of real-world evidence. You've seen many countries showing 80% ...

Sanofi and partner AstraZeneca’s AZN RSV antibody Beyfortus (nirsevimab) recorded sales of €841 million in the fourth quarter, up 107% year over year, driven by higher sales in the United ...

Sanofi (NASDAQ: SNY) Q4 2024 Earnings Call Jan 30, 2025, 9:00 a.m. ET Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. Contents: Prepared Remarks ...

states and territories are picking up the tab for Sanofi-Aventis’ nirsevimab (sold as Beyfortus) for infants. This is widely used, and funded, in the US and Europe. The cost of the vaccine is $300.